Further research is necessary to characterize the relationship between PSMA expression and ADT/ARSi initiation and understand how changes in PSMA-PET features correlate with clinical response criteria in PCa patients initiating treatment with ADT/ARSi. The gene discussed is FOLH1; the disease is posterior cortical atrophy.